Fail

A Hazy Shade of Winter – Part 3 (TYME)

Today’s the day. The day a filthy reverse merger bioturd called Tyme Technologies hosts a conference call to discuss the early results from it’s ongoing study of SM-88, a cocktail of 3 already approved drugs plus their magic Tyrosine.

We’ve already examined the birth of TYME, and its relationship to not one, but two, sanctioned lawyers and one moonlighting sell side shill, in Part 1, here. We’ve also looked at the four clinical trials testing SM-88, and learned that not a single one is truly legitimate. These “studies” have neither control arms nor double-blinding. Read more about them in Part 2, here.

Right now let’s look at the early data for the pancreatic cancer study, NCT03512756. It can be found in this abstract.

tyme-results

So, although the original study plan was for 115 participants, as of September 2018 the company had only managed to enroll 36.

Of these 36 subjects, only 83% (30/36) remained on treatment. What happened to the other 6?

Of the 30 that remained on treatment, only 16 were “evaluable” for CTC (Circulating Tumor Cell) blood testing. What happened to the other 14?

Of the 16 that received CTC tests, 11 showed reductions. Sounds impressive, but something is off about this. Nowhere in the clinical trial record does it actually mention CTCs as being an outcome measure! The only listed outcome measure of this study is Overall Response Rate using RECIST 1.1:

tyme-outcome

The abstract continues, mentioning that 2 of 9 subjects showed CA19.9 (a tumor marker for pancreatic cancer) declines. But CA19.9 is not an outcome measure. And where did this group of 9 patients come from? What happened to the others?

Less and less patients seem to be available as the abstract continues. Only 6 were eligible for the initial scheduled assessment. And 3 of 4 had what the company called “RECIST or PET SUV responses”.

What happened to the other 2 out of 6? And why the change from using only RECIST as the outcome measurement? PET SUV is not part of the study protocol. One can be sure that if the patients actually had a true RECIST response, PET SUV would never have been mentioned.

One can expect the scum behind this biodreck to hype these results, 3/4 = 75% ORR using their bucket shop math, but the real number, if one wanted to look at this data in the most favorable light possible is that only 3/36 patients had a measurable response.

36 patients enrolled

30 patients remained on treatment

16 patients were evaluable for CTC – Not a real, specified, outcome measure.

9 patients evaluable for CA19.9 – Not a real, specified, outcome measure.

6 patients made it to initial assessment

4 patients were actually evaluated

3 patients had a response using a non-standard criteria not in the clinical trial plan

3/36. That’s 8.3%. In an unblinded study. And even then, the study is so poorly designed it is impossible to tell which agent, or agents, had any activity.

Fail.

THE CONTENT CONTAINED IN THIS BLOG REPRESENTS ONLY THE OPINIONS OF THE AUTHOR. THE AUTHOR MAY HOLD EITHER LONG OR SHORT POSITIONS IN SECURITIES OF VARIOUS COMPANIES DISCUSSED IN THE BLOG. THIS COMMENTARY IN NO WAY CONSTITUTES INVESTMENT ADVICE, AND SHOULD NEVER BE RELIED ON IN MAKING AN INVESTMENT DECISION, EVER. THIS BLOG IS NOT A SOLICITATION OF BUSINESS: ALL INQUIRIES WILL BE IGNORED. THE CONTENT HEREIN IS INTENDED SOLELY FOR THE ENTERTAINMENT OF THE READER, AND THE AUTHOR.

 

Advertisements

A Hazy Shade of Winter – Part 2 (TYME)

As we explored in Part 1, the provenance of Tyme Technologies (TYME) is hardly encouraging. We have a saying at BuyersStrike! HQ, “Past is prologue, always” but some might argue that past association with notorious scam lawyers Diane Harrison and Adam Gottbetter, along with a shady IR/bucket shop shill, Raghuram Selvaraju, doesn’t reflect the amazing potential of Tyme’s cancer treatment, SM-88.

Quite the contrary, Tyme’s past completely predicts Tyme’s nonsense treatment, its poorly designed trials, and its terrible efficacy.

SM-88 is actually a combination of four compounds, three of which are already approved drugs, easily available.

Sirolimus aka Rapamune (rapamycin)

Dilantin (phenytoin)

Uvadex (methoxsalen)

and

“Magic” Tyrosine (a modified form of Tyrosine, a non-essential amino acid)

Rapamune and related drug Afinitor are already used in oncology. So is Uvadex. Dilantin was once commonly prescribed to brain cancer patients for seizure suppression, but there have not been any reports of improved outcomes with Dilantin therapy.

With 2 known, and potentially 4 active compounds in this cocktail, one would think a study should have at least two arms:

  1. SM-88 arm (R+D+U+mT)
  2. R+D+U arm (active comparator)

Or better yet, to be considered well designed, at least 8 arms:

  1. SM-88 arm
  2. Rapamune only arm
  3. Dilantin only arm
  4. Uvadex only arm
  5. R+D+U arm
  6. R+D arm
  7. R+U arm
  8. D+U arm

Let’s see what clinical trials the good people at Tyme are actually running.

(more…)

Kalem, Kukekov and some piece of shit medical device reverse merger in Eden Prairie – (NMTC)

A reverse-merger based in Eden Prairie, MN, hyping nonsense, recently came to our attention, NeuroOne Medical Technologies (NMTC). This filthy company shares many similarities to another reverse-merger turd, Biotricity (BTCY), we’ll examine that scam another time. For now, let’s look under the covers at NMTC.

There was recently a conversion of notes at $1.80/shr, along with 100% warrant coverage at $1.80. Our guess is that we are seeing a walk-up (aka a “rig”) in front of a real promotion as those shares are being sold.

The company originally came public in 2011, as Original Source Entertainment, a Jody Walker shell. Ms. Walker has been responsible for countless scams: RNBI, ALKM, VHUB, RIHT, RJDG, PVTA, KRED, NAMG, DMHI, and AIDC just to start.

The original nominee holders were:

NMTC-OriginalNominees

In 2014, the control block was sold to a young gentleman named, Amer Samad:

NMTC-SaletoAmer2014

Amer moved the company to an address near Buffalo, NY. By April, 2017 some stock had leaked out, and Amer still held 69% control.

NMTC_ownership_april2017

In July 2017, the shell merged with a medical device company in Minnesota, NeuroOne, Inc., creating NeuroOne Medical Technologies (NMTC). Curiously Amer returned 100% of his holdings for cancellation.

NMTC-AmerCancellation

This leaves 1.573mm existing shares, and 6.292mm shares issued in the merger for a total outstanding of 7.865mm shares. One unanswered question is where did those existing shares, which would be free-trading, end up? Typically in these sorts of scams, these shares are actually secretly in the hands of the promoters/insiders. Another question is who has been paying Amer? An unnamed related party.

NMTC-WhoPaidAmer

Just who is this related party? That remains unanswered (for now) as well, but at BuyersStrike! HQ we have some ideas.

The merger into the shell was arranged by an outfit called Highline Research Advisors (HRA), which is made up a few ex-John Thomas Financial (expelled by FINRA, raided by Feds), ex-Merriman (expelled by FINRA), ex-Agincourt rejects, Theodore Kalem & Nikolay Kukekov. Their HRA shop has moved from JTF to Merriman to Agincourt and now they hang their hats at another bucket shop, Corinthian Partners.

Here’s Theodore’s CRD:

NMTC-TedKalemCRD

And Nickolay’s:

NMTC-Nikolay-CRD

The working theory here at HQ is that finding this shell was no chance occurrence for Kalem and Kukekov. Mr. Samad‘s name appears in a previous Kalem/Kukekov deal, Citius (CTXR). See the CTXR S-1 filed September 11, 2015. Given that they probably knew Amer from this prior turkey, it is highly likely that one of them, or an entity they control, was the related party funding the shell.

After the NMTC merger the new shareholder list looked something like this, from the most recent NMTC proxy, filed April 27, 2018.

NMTC-Proxy-2018Holders

Would it surprise you, dear reader, to learn that there are shenanigans afoot? Chromium 24 LLC and Lifestyle Healthcare LLC are actually undisclosed related parties. Their total ownership is over 18%. Likely tripping up all sorts of disclosure violations, just for a start. 

How are they related?

When pulling the ownership statement for Chromium 24, LLC we find a familiar family name, Kalem:

NMTC-Chromium2413d

“That’s only a coincidence,” the touts and shills might say. Perhaps, perhaps not. Let’s dig deeper, from Bloomberg:

BTCY-Chromium24Owners

And how about Lifestyle Healthcare, LLC? Let’s read Nickolay’s biography carefully:

NMTC-Lifestyle-Nikolay

Kukekov is an owner of both entities, and clearly has a close relationship with Kalem. Case closed. And this is not the only piece of garbage bioturd/medical device scam stock with these two fine gentlemen lurking behind the scenes.

The content contained in this blog represents only the opinions of the author. The author may hold either long or short positions in securities of various companies discussed in the blog. This commentary in no way constitutes investment advice, and should never be relied on in making an investment decision, ever. This blog is not a solicitation of business: all inquiries will be ignored. The content herein is intended solely for the entertainment of the reader, and the author.

 

 

 

The Map and the Territory: Who Controls Gopher Protocol? – GOPH

As part of our continuing series on filthy reverse merger Gopher Protocol (GOPH), we’ll start to explore exactly who controls the company.

Just looking at common stock is not enough, one must look at the various series of convertible bonds, warrants, and preferred stock. Some of which have conversion prices under 1c!

Here is a snapshot of GOPH ownership from before the stock promotion began in earnest. These numbers have certainly changed.

The short answer, is Galina Vaynter, through various entities and related parties. These include companies headed by her husband, Avady aka Vadim Vaynter, her daughter Regina Kats, and various straw men and women, including this guy, Kenneth Jeremy Smith, in Spokane, WA.

KJSmithEDIT

Together, these account for at least 85% control of GOPH (and possibly more) before the promotion started in earnest. See here:

WhoControlsGOPH-map

There’s lots more to come….

THE CONTENT CONTAINED IN THIS BLOG REPRESENTS ONLY THE OPINIONS OF THE AUTHOR. THE AUTHOR MAY HOLD EITHER LONG OR SHORT POSITIONS IN SECURITIES OF VARIOUS COMPANIES DISCUSSED IN THE BLOG. THIS COMMENTARY IN NO WAY CONSTITUTES INVESTMENT ADVICE, AND SHOULD NEVER BE RELIED ON IN MAKING AN INVESTMENT DECISION, EVER. THIS BLOG IS NOT A SOLICITATION OF BUSINESS: ALL INQUIRIES WILL BE IGNORED. THE CONTENT HEREIN IS INTENDED SOLELY FOR THE ENTERTAINMENT OF THE READER, AND THE AUTHOR.

 

A Brief List of Gopher Protocol CEOs and Addresses – GOPH/FXIT

In today’s installment of our continuing series of investigations into the stock promotion known as Gopher Protocol (GOPH), we’ll look at the revolving door of CEOs and the many addresses from where the company has claimed to be operating.

In its first incarnation, GOPH was known as Forex International Trading Corp, and traded under the ticker FXIT. The very first records indicate that the CEO was Moshe J. Schnapp, and the company headquarters were at 1618 N. Fairfax Avenue Los Angeles, California 90046.

Schnapp is an Israeli citizen living in California. He left Israel owing a large sum to Israel Discount Bank (IDB). IDB has since been active in US courts, trying to “Mo J” to pay what he owes. Interested readers can learn more about IDB vs Schnapp here.

MosheSchnapp

Moshe J. Schnapp

Schnapp had a previous run as an officer at Yasheng Eco-Trade (BOPT) aka Eco-Trade aka Euroweb aka Emvelco, an eerily similar scam to GOPH.

(more…)

The Map and the Territory Updated- GOPH, HMNY, YAYO, GENI, BOPT, FTMK & USXP(!)

Now updated to include Darren Dunckel, scum stock lawyer Stephen Fleming, links to notorious stock promotion Universal Express (USXP), and some very bad Russians (Vaynters, Guss) and Israelis (Attia, Schnapp) living in LA.

GOPH-Map

More on Gopher Protocol to come.

THE CONTENT CONTAINED IN THIS BLOG REPRESENTS ONLY THE OPINIONS OF THE AUTHOR. THE AUTHOR MAY HOLD EITHER LONG OR SHORT POSITIONS IN SECURITIES OF VARIOUS COMPANIES DISCUSSED IN THE BLOG. THIS COMMENTARY IN NO WAY CONSTITUTES INVESTMENT ADVICE, AND SHOULD NEVER BE RELIED ON IN MAKING AN INVESTMENT DECISION, EVER. THIS BLOG IS NOT A SOLICITATION OF BUSINESS: ALL INQUIRIES WILL BE IGNORED. THE CONTENT HEREIN IS INTENDED SOLELY FOR THE ENTERTAINMENT OF THE READER, AND THE AUTHOR.

The Map and the Territory – GOPH, HMNY, YAYO, GENI, BOPT

Just for a start….

GOPH-Map

For more on Gopher Protocol, see yesterday’s post.

THE CONTENT CONTAINED IN THIS BLOG REPRESENTS ONLY THE OPINIONS OF THE AUTHOR. THE AUTHOR MAY HOLD EITHER LONG OR SHORT POSITIONS IN SECURITIES OF VARIOUS COMPANIES DISCUSSED IN THE BLOG. THIS COMMENTARY IN NO WAY CONSTITUTES INVESTMENT ADVICE, AND SHOULD NEVER BE RELIED ON IN MAKING AN INVESTMENT DECISION, EVER. THIS BLOG IS NOT A SOLICITATION OF BUSINESS: ALL INQUIRIES WILL BE IGNORED. THE CONTENT HEREIN IS INTENDED SOLELY FOR THE ENTERTAINMENT OF THE READER, AND THE AUTHOR.